The role of CAR T-cell therapy for treating myeloma in the era of bispecific antibodies

Saad Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY, discussed the unprecedented response rates in heavily pretreated patients with multiple myeloma (MM) treated with CAR T-cell therapies and other immunotherapies, highlighting the potential benefits and challenges of these treatments. Dr Usmani notes that, while CAR-T therapies offer a one-time treatment option with no maintenance therapy, they are associated with challenges such as manufacturing time, patient eligibility, and access. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.